Idera Pharmaceuticals

  About Idera

  CLINICAL Programs &
  Pipeline

  Discovery

  Collaborations

  Partnering Opportunities

  Investors

news & events | pipeline | search | careers | contact us

News & Events

06.05.2013

Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis

05.15.2013

Idera Pharmaceuticals Reports First Quarter 2013 Financial Results

[ view all press releases ]

About Idera

Idera Pharmaceuticals is a clinical stage biotechnology company developing a novel approach to the potential treatment of autoimmune and inflammatory diseases.

Idera’s drug candidates are designed to modulate immune responses through Toll-like Receptors (TLRs).

Idera also is collaborating with Merck & Co. for TLR-targeted compounds for use as vaccine adjuvants.

 

Therapeutic Areas

> AUTOIMMUNE DISEASES
> VACCINE ADJUVANTS

Partnering Opportunities

> CANCER
> RESPIRATORY DISEASES
> INFECTIOUS DISEASES
> TLR3 AGONISTS
> GENE-SILENCING OLIGONUCLEOTIDES

 

Boston Web Design